Tag Archives: Jounce Therapeutics

June, 2017

January, 2017

  • 4 January

    Jounce Therapeutics Files for $75M IPO

    CAMBRIDGE, Mass., January 3, 2017 –Jounce Therapeutics, a clinical-stage immuno-oncology company, has filed an initial public offering  through which it hopes to raise $75 million in 2017. The Cambridge, MA-based company was founded in 2012 and employs a two-pronged approach to therapy development: using a translational science platform that targets …

July, 2016

  • 19 July

    Celgene and Jounce Therapeutics Enter Cancer Immunotherapy Collaboration

    CAMBRIDGE, Mass., July 19, 2016 – Jounce Therapeutics, Inc., a company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers for patient enrichment, today announced a global strategic collaboration with Celgene Corporation (NASDAQ: CELG) focused on developing and commercializing innovative immuno-oncology treatments for patients with cancer. …

April, 2015